Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials

Zanetta C, Nizzardo M, Simone C, Monguzzi E, Bresolin N, Comi GP, Corti S.
Clin Ther. 2014. 1;36(1):128-40.
This article provides a general overview of the main aspects that need to be taken into account to design a more efficient clinical trial and to summarize the most promising molecular trials that are currently in development or are being planned for the treatment of Spinal Muscular Atrophy (SMA).

PubMed link

Keywords: clinical trials, gene therapy, ISIS- SMNRx, olesoxime, oligonucleotides, small molecules, spinal muscular atrophy

 

Articles dans les revues scientifiques

Short-TERM Neuromuscular Electrical Stimulation Training of the Tibialis Anterior Did Not Improve Strength and Motor Function in Facioscapulohumeral Muscular Dystrophy Patients

Doix AM, Roeleveld K, Garcia J, Lahaut P, Tanant V, Fournier-Mehouas M, Desnuelle C, Colson SS, Sacconi S Am J Phys Med Rehabil. 2017. 96(4):e56-e63. Prospective study including 10 patients with facioscapulohumeral muscular dystrophy type 1 (FSHD1) and 10 healthy...

read more